Genetic Engineering & Biotechnology News

11/07/2025

NEW WEBINAR! Scaling Cell Therapy Development from Research to Commercialization

Broadcast Date: Wednesday, December 3, 2025
Time: 08:00 PST, 11:00 EST, 16:00 GMT

In this GEN webinar, Nik Ekman will discuss critical considerations for scaling cell therapy processes from research through commercialization. During the webinar, you will learn how designing flexible, closed, compliant workflows early drives efficiency, quality, and sterility assurance across cell therapy development.

Register now to join us for this free webinar sponsored by CPC - Colder Products Company: https://hubs.li/Q03RWzZZ0

11/06/2025

FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

The U.S. Food and Drug Administration approved UCB’s KYGEVVI, the first treatment for thymidine kinase 2 deficiency (TK2d), an ultra-rare fatal mitochondrial disease, reducing death risk by 86% in patients with early symptom onset.

United Mitochondrial Disease Foundation, Columbia University Irving Medical Center

FDA approved KYGEVVI, the first and only treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients.

11/06/2025

New eBook! Beyond Antibodies: Unlocking New Targets and Applications with Optimer

This eBook explores the science and applications behind these advances. Through case studies and examples, it highlights how Optimers are accelerating discovery, enabling more precise therapeutic strategies, and transforming the way researchers approach previously intractable biological questions. As the pace of innovation accelerates, Optimers are opening doors to possibilities once thought out of reach to help make science unlimited.

Download this FREE eBook sponsored by Aptamer Group: https://hubs.li/Q03R1SF10

11/06/2025

Creating Space for Smarter Drug Discovery

Drug discovery is becoming more personalized, and the methods used to generate therapeutic insights are advancing alongside it. Spatial biology tools let researchers interrogate tissue function, cell interactions, and physiological or pathological processes at single-cell resolution.

Drug discovery is becoming more personalized, and the methods used to generate therapeutic insights are advancing alongside it. Spatial biology tools let researchers interrogate tissue function, cell interactions, and physiological or pathological processes at single-cell resolution.

11/06/2025

Acyclovir-Activated Poison Exon Enables Reversible Gene Expression

A new gene-switch tool called Cyclone uses a nontoxic antiviral drug to reversibly control gene expression without altering native transcripts, potentially offering a safer alternative to existing systems.

Weill Cornell Medicine

Cyclone is a portable gene-switch system that uses acyclovir to reversibly control gene expression with minimal toxicity.

11/05/2025

Non-Surgical Brain Implants Provide Targeted Neuromodulation in Mice

A new study presents microscopic, wireless bioelectronics that can autonomously self-implant in a target region of the brain to provide neuromodulation to treat brain tumors and diseases, such as Alzheimer’s and multiple sclerosis.

Massachusetts Institute of Technology (MIT)

In a new study, microscopic bioelectronics can autonomously self-implant in a target region of the brain to treat brain tumors and diseases.

11/05/2025

MARK YOUR CALENDAR! Enhancing Speed and Scalability in Upstream Bioprocessing of Monoclonal and Bispecific Antibodies

Broadcast Date: Monday, November 10, 2025
Time: 08:00 PST, 11:00 EST, 16:00 GMT

In this GEN webinar, a distinguished panel of experts discuss next-generation expression systems, optimized screening methods, and integrated development strategies that are enabling higher-performing monoclonal and bispecific antibody production pipelines. The discussion will spotlight practical strategies that can accelerate upstream development processes while mitigating risk and ensuring long-term success.

Register now to join us for this free webinar sponsored by Thermo Fisher Scientific: https://hubs.li/Q03Q2zRN0

11/05/2025

Novel Leukemia Drug Targets May Lie Within Nuclear Condensates

Different genetic drivers of leukemia appear to use the same secret compartments—known as C-bodies—inside the cell nucleus to keep cancer growing, which may point to a shared physical therapeutic target.

Baylor College of Medicine

Study reshapes view of how a common leukemia begins and could point to new therapeutic strategies targeting a common weakness.

11/05/2025

From Birthplace of Jazz, Startup Swings with Non-Opioid Pain Treatments

A spinout from LSU Health New Orleans School of Medicine, from which it licenses technology, South Rampart is developing non-opioid analgesics led by an oral form of its sole pipeline candidate SRP-001. The Phase II-ready non-NSAID is an AM404 agonist designed to target the endocannabinoid (CB1) pain receptors in the brain.

, National Institutes of Health (NIH), Vertex

South Rampart Pharma is working to develop an oral small molecule non-opioid pain treatment which has generated early positive clinical data as a therapy for acute and chronic pain, as well as preclinical studies in diabetic and chemotherapy neuropathy.

11/05/2025

Missed it live? The State of AI in Drug Discovery is now on demand. Stream the full program.

What you’ll see:
• The Business of AI in Drug Discovery with Derek Lowe (Novartis), Molly Gibson (Flagship Pioneering), and Stacie Calad-Thomson (NVIDIA)
• Bo Wang (Xaira) on multimodal AI for health care
• Boltz-2 with Corso, Barzilay, and Khan
• Building the virtual cell with CZI, Arc Institute, and Noetik
• The next wave in AI-driven protein design with Nabla Bio, Generate, and Basecamp Research

Watch free, anytime: https://hubs.li/Q03RK7-d0

11/05/2025

First-Ever Cellular Atlas of the Aedes aegypti Mosquito

The freely available Mosquito Cell Atlas provides cellular-level resolution of gene expression in every mosquito tissue.

The freely available Mosquito Cell Atlas provides cellular-level resolution of gene expression in every mosquito tissue.

11/05/2025

Cardiac Repair Promoted by Cyclin A2, Potential Heart Transplant Alternative

The new Icahn School of Medicine at Mount Sinai study shows a translational bridge, in which a human-compatible viral vector can safely and effectively trigger cell division in adult human heart cells.

The Cyclin A2 gene (CCNA2), which turns off after birth in humans, can promote cardiac repair in adult human cardiomyocytes.